Nature Communications (Apr 2021)

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

  • Cathrine Axfors,
  • Andreas M. Schmitt,
  • Perrine Janiaud,
  • Janneke van’t Hooft,
  • Sherief Abd-Elsalam,
  • Ehab F. Abdo,
  • Benjamin S. Abella,
  • Javed Akram,
  • Ravi K. Amaravadi,
  • Derek C. Angus,
  • Yaseen M. Arabi,
  • Shehnoor Azhar,
  • Lindsey R. Baden,
  • Arthur W. Baker,
  • Leila Belkhir,
  • Thomas Benfield,
  • Marvin A. H. Berrevoets,
  • Cheng-Pin Chen,
  • Tsung-Chia Chen,
  • Shu-Hsing Cheng,
  • Chien-Yu Cheng,
  • Wei-Sheng Chung,
  • Yehuda Z. Cohen,
  • Lisa N. Cowan,
  • Olav Dalgard,
  • Fernando F. de Almeida e Val,
  • Marcus V. G. de Lacerda,
  • Gisely C. de Melo,
  • Lennie Derde,
  • Vincent Dubee,
  • Anissa Elfakir,
  • Anthony C. Gordon,
  • Carmen M. Hernandez-Cardenas,
  • Thomas Hills,
  • Andy I. M. Hoepelman,
  • Yi-Wen Huang,
  • Bruno Igau,
  • Ronghua Jin,
  • Felipe Jurado-Camacho,
  • Khalid S. Khan,
  • Peter G. Kremsner,
  • Benno Kreuels,
  • Cheng-Yu Kuo,
  • Thuy Le,
  • Yi-Chun Lin,
  • Wu-Pu Lin,
  • Tse-Hung Lin,
  • Magnus Nakrem Lyngbakken,
  • Colin McArthur,
  • Bryan J. McVerry,
  • Patricia Meza-Meneses,
  • Wuelton M. Monteiro,
  • Susan C. Morpeth,
  • Ahmad Mourad,
  • Mark J. Mulligan,
  • Srinivas Murthy,
  • Susanna Naggie,
  • Shanti Narayanasamy,
  • Alistair Nichol,
  • Lewis A. Novack,
  • Sean M. O’Brien,
  • Nwora Lance Okeke,
  • Léna Perez,
  • Rogelio Perez-Padilla,
  • Laurent Perrin,
  • Arantxa Remigio-Luna,
  • Norma E. Rivera-Martinez,
  • Frank W. Rockhold,
  • Sebastian Rodriguez-Llamazares,
  • Robert Rolfe,
  • Rossana Rosa,
  • Helge Røsjø,
  • Vanderson S. Sampaio,
  • Todd B. Seto,
  • Muhammad Shahzad,
  • Shaimaa Soliman,
  • Jason E. Stout,
  • Ireri Thirion-Romero,
  • Andrea B. Troxel,
  • Ting-Yu Tseng,
  • Nicholas A. Turner,
  • Robert J. Ulrich,
  • Stephen R. Walsh,
  • Steve A. Webb,
  • Jesper M. Weehuizen,
  • Maria Velinova,
  • Hon-Lai Wong,
  • Rebekah Wrenn,
  • Fernando G. Zampieri,
  • Wu Zhong,
  • David Moher,
  • Steven N. Goodman,
  • John P. A. Ioannidis,
  • Lars G. Hemkens

DOI
https://doi.org/10.1038/s41467-021-22446-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/ ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95% CI: 1.02, 1.20; I² = 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I² = 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.